Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: Results from a phase IV clinical trial

International Clinical Psychopharmacology

Volumn 30, Issue 4, 2015, Pages 216-223

  Clayton, Anita H ^a   Gommoll, Carl ^b   Chen, Dalei ^b   Nunez, Rene ^b   Mathews, Maju ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Antidepressant; Changes in Sexual Functioning Questionnaire; post hoc analyses; selective serotonin reuptake inhibitor; sexual dysfunction; vilazodone

Indexed keywords

CITALOPRAM; PLACEBO; VILAZODONE; ANTIDEPRESSANT AGENT; SEROTONIN 1 AGONIST; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANORGASMIA; ARTICLE; ASSESSMENT OF HUMANS; CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; ERECTILE DYSFUNCTION; FEMALE; FEMALE SEXUAL DYSFUNCTION; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MALE SEXUAL DYSFUNCTION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PREMATURE EJACULATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; TREATMENT RESPONSE; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; MIDDLE AGED; PARTIAL AGONISM; PSYCHOLOGY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG PARTIAL AGONISM; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VILAZODONE HYDROCHLORIDE;

EID: 84931080168     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000075     Document Type: Article

References (20)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, text revision, 4th ed. Washington, DC: American Psychiatric Association.
2. Angst J (1998). Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 13 (Suppl 6):S1-S4.
3. Ashton AK, Jamerson BD, Weinstein LW, Wagoner C (2005). Antidepressantrelated adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp 66:96-106.
4. Atlantis E, Sullivan T (2012). Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med 9:1497-1507.
5. Bobes J, Gonzalez MP, Bascaran MT, Clayton A, Garcia M, Rico-Villade Moros F, Banús S (2002). Evaluating changes in sexual functioning in depressed patients: sensitivity to change of the CSFQ. J Sex Marital Ther 28:93-103.
6. Bonierbale M, Lancon C, Tignol J (2003). The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 19:114-124.
7. Clayton AH, McGarvey EL, Clavet GJ, Piazza L (1997). Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 33:747-753.
8. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M (2007). Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 4 (Pt 1):917-929.
9. Clayton AH, Kennedy SH, Edwards JB, Gallipoli S, Reed CR (2013). The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med 10:2465-2476.
10. Clayton AH, Croft HA, Handiwala L (2014). Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med 126:91-99.
11. Giuliano F, Clement P (2005). Physiology of ejaculation: emphasis on serotonergic control. Eur Urol 48:408-417.
12. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE (2004). Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 65:959-965.
13. Kennedy SH, Rizvi S (2009). Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 29:157-164.
14. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, et al. (2011). A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 72:441-447.
15. Mathews M, Gommoll C, Chen D, Nunez R, Khan A (2015). Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, doubleblind, placebo-controlled trial. Int Clin Psychopharmacol 30:67-74.
16. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R (2000). The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26:25-40.
17. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
18. Oosting RS, Olivier B, Chan J, Banerjee P (2013). Vilazodone exhibits a favorable sexual adverse effect profile in male rats. Poster presented at the 166th Annual American Psychiatric Association Meeting; San Francisco, CA.
19. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR (2009). Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70:326-333.
20. Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR (2011). A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 31:643-646.